Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 13/20 | 0.58 |
| ▸ | AKT2 | P31751 | 2/20 | 0.49 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 5/20 | 0.47 |
| ▸ | JAK1 | P23458 | 5/20 | 0.47 |
| ▸ | TYK2 | P29597 | 4/20 | 0.47 |
| ▸ | AKT1 | P31749 | 2/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL324612 | 0.89 | JAK3 (0.61) | JAK3AKT2KITLCKJAK2 | |
| SCHEMBL324665 | 0.89 | JAK3 (0.64) | JAK3AKT2KITLCKJAK2 | |
| SCHEMBL322694 | 0.87 | JAK3 (0.62) | JAK3LCKJAK2JAK1TYK2 | |
| SCHEMBL324225 | 0.86 | AKT2 (0.58) | JAK3AKT2KITLCKJAK2 | |
| SCHEMBL322721 | 0.85 | JAK3 (0.62) | JAK3AKT2KITAKT1RPS6KB1 | |
| SCHEMBL10232195 | 0.85 | JAK3 (0.56) | JAK3AKT2KITLCKJAK2 | |
| SCHEMBL322847 | 0.85 | JAK3 (0.61) | JAK3AKT2LCKJAK2JAK1 | |
| SCHEMBL325109 | 0.84 | JAK3 (0.61) | JAK3AKT2KITLCKAKT1 | |
| SCHEMBL323780 | 0.84 | JAK3 (0.61) | JAK3AKT2KITLCKJAK2 | |
| SCHEMBL323240 | 0.84 | JAK3 (0.61) | JAK3AKT2KITLCKJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | claimed |
| EP-2590981-B1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2014-09-03 | — | — | EP | claimed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | claimed |
| EP-2590981-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-05-15 | — | — | EP | claimed |
| WO-2012003829-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-01-12 | — | — | WO | claimed |
| US-9586961-B2 | Homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA A/S (DK) | 2017-03-07 | — | — | US | disclosed |
| EP-2590981-B1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2014-09-03 | — | — | EP | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2013-07-04 | — | — | US | disclosed |
| EP-2590981-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012003829-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA A/S (DK) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172325-A1 | NOVEL HOMOPIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | JAK1, JAK2, JAK3 | JAK3 3/4885AKT2 713/4885KIT 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.